LV10394B - Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix - Google Patents

Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix Download PDF

Info

Publication number
LV10394B
LV10394B LVP-93-753A LV930753A LV10394B LV 10394 B LV10394 B LV 10394B LV 930753 A LV930753 A LV 930753A LV 10394 B LV10394 B LV 10394B
Authority
LV
Latvia
Prior art keywords
quot
antigen
iskom
solubilizing agent
indicated
Prior art date
Application number
LVP-93-753A
Other languages
English (en)
Latvian (lv)
Other versions
LV10394A (lv
Inventor
Mackenzie Neill Moray
O'sullivan Angela Marie
Original Assignee
Mallinckrodt Veterinary Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Veterinary Ltd filed Critical Mallinckrodt Veterinary Ltd
Publication of LV10394A publication Critical patent/LV10394A/xx
Publication of LV10394B publication Critical patent/LV10394B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-93-753A 1989-09-01 1993-06-29 Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix LV10394B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898919819A GB8919819D0 (en) 1989-09-01 1989-09-01 Complexes having adjuvant activity
PCT/GB1990/001351 WO1991003256A1 (en) 1989-09-01 1990-08-31 Adjuvant complexes

Publications (2)

Publication Number Publication Date
LV10394A LV10394A (lv) 1995-02-20
LV10394B true LV10394B (en) 1995-10-20

Family

ID=10662403

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-753A LV10394B (en) 1989-09-01 1993-06-29 Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix

Country Status (15)

Country Link
EP (2) EP0415794A1 (ja)
JP (1) JPH05500056A (ja)
AU (1) AU637405B2 (ja)
CA (1) CA2064911A1 (ja)
DD (1) DD297331A5 (ja)
GB (1) GB8919819D0 (ja)
HU (1) HU214110B (ja)
IE (1) IE903161A1 (ja)
LV (1) LV10394B (ja)
NZ (1) NZ235119A (ja)
PL (2) PL168055B1 (ja)
PT (1) PT95164B (ja)
WO (1) WO1991003256A1 (ja)
YU (1) YU166790A (ja)
ZA (1) ZA906977B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) * 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN114404583A (zh) * 2022-01-25 2022-04-29 龙岩学院 一种副猪嗜杆菌佐剂疫苗的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
AU2297888A (en) * 1988-09-30 1990-04-05 Lovgren, Karin A complex comprising adjuvants and lipids
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes

Also Published As

Publication number Publication date
WO1991003256A1 (en) 1991-03-21
DD297331A5 (de) 1992-01-09
PL168316B1 (pl) 1996-02-29
PL286711A1 (en) 1991-07-15
PT95164B (pt) 1997-09-30
JPH05500056A (ja) 1993-01-14
AU637405B2 (en) 1993-05-27
PL168055B1 (pl) 1995-12-30
IE903161A1 (en) 1991-03-13
ZA906977B (en) 1992-05-27
NZ235119A (en) 1991-12-23
PT95164A (pt) 1991-05-22
CA2064911A1 (en) 1991-03-02
GB8919819D0 (en) 1989-10-18
LV10394A (lv) 1995-02-20
HU9200666D0 (en) 1992-05-28
EP0766967A1 (en) 1997-04-09
YU166790A (sh) 1994-12-28
HU214110B (en) 1997-12-29
EP0415794A1 (en) 1991-03-06
AU6335590A (en) 1991-04-08
HUT61205A (en) 1992-12-28

Similar Documents

Publication Publication Date Title
LV10394B (en) Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix
Bullen et al. Bacterial iron metabolism in infection and immunity
Mayr et al. Bacterial ghosts as antigen delivery vehicles
Knickelbein et al. Membrane distribution of sodium-hydrogen and chloride-bicarbonate exchangers in crypt and villus cell membranes from rabbit ileum.
Kennedy et al. Effects of Escherichia coli heat-stable enterotoxin STb on intestines of mice, rats, rabbits, and piglets
CN101896197B (zh) 来自艰难梭菌的新型多糖免疫原
van Putten et al. Molecular mechanisms of Campylobacter infection
Jena et al. Probiotics VSL# 3 are effective in reversing non-alcoholic steatohepatitis in a mouse model
EP0293751B1 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
EP2384190B1 (en) Formulations of viable cells for oral delivery
Dinari et al. Local and systemic antibody responses to Shigella infection in rhesus monkeys
Fuller et al. Legionnaires' disease after heart transplantation
Karlsson et al. Unexpected carbohydrate cross-binding by Escherichia coli heat-labile enterotoxin. Recognition of human and rabbit target cell glycoconjugates in comparison with cholera toxin
Crowlesmith et al. Bacteriophage P22 is not a likely probe for zones of adhesion between the inner and outer membranes of Salmonella typhimurium
Johnson et al. Uptake and subcellular localization of tritiated spermine in Escherichia coli
Hiroshi et al. Inhibition of drug-metabolizing enzymes in the mouse after treatment with host-mediating antitumor drugs
Richardson et al. A novel cold-chain free VCG-based subunit vaccine protects against Chlamydia abortus-induced neonatal mortality in a pregnant mouse model
WO2021077113A1 (en) Methods of treatment of bladder cancer by using modified bacillus calmette-guérin
US20190117684A1 (en) Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6
Portelance et al. Toxic effects of massive doses of BCG in mice, guinea pigs, and monkeys
Hase et al. Contributions of Japanese Scholars to Advances in Clinical TB Management: In TB World, What Kind of Achievements Are Accomplished by Japanese Researchers?
Midtvedt Metabolism of endogenous substances
Ahmed et al. Survival and protection of Lactococcus lactis in the porcine gastrointestinal tract: a step towards the validation of the L. lactis-based EHEC vaccine in pig models
Osada et al. Chemotherapeutic evaluation of rifampicin to experimental bacillary dysentery in cynomolgus monkeys
Reggiardo Antitumor activity of mycobacterial glycolipid A1